Literature DB >> 22497674

Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations.

Seth S Martin, Thomas S Metkus, Aaron Horne, Michael J Blaha, Rani Hasan, Catherine Y Campbell, Omair Yousuf, Parag Joshi, Sanjay Kaul, Michael Miller, Erin D Michos, Steven R Jones, Ty J Gluckman, Christopher P Cannon, Laurence S Sperling, Roger S Blumenthal.   

Abstract

The National Cholesterol Education Program Adult Treatment Panel (ATP) has provided education and guidance for decades on the management of hypercholesterolemia. Its third report (ATP III) was published 10 years ago, with a white paper update in 2004. There is a need for translation of more recent evidence into a revised guideline. To help address the significant challenges facing the ATP IV writing group, this statement aims to provide balanced recommendations that build on ATP III. The authors aim for simplicity to increase the likelihood of implementation in clinical practice. To move from ATP III to ATP IV, the authors recommend the following: (1) assess risk more accurately, (2) simplify the starting algorithm, (3) prioritize statin therapy, (4) relax the follow-up interval for repeat lipid testing, (5) designate <70 mg/dl as an "ideal" low-density lipoprotein cholesterol target, (6) endorse targets beyond low-density lipoprotein cholesterol, (7) refine therapeutic target levels to the equivalent population percentile, (8) remove misleading descriptors such as "borderline high," and (9) make lifestyle messages simpler. In conclusion, the solutions offered in this statement represent ways to translate the totality of published reports into enhanced hyperlipidemia guidelines to better combat the devastating impact of hyperlipidemia on cardiovascular health.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22497674     DOI: 10.1016/j.amjcard.2012.03.023

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Impact on cognitive function-are all statins the same?

Authors:  Nishant P Shah; Kristopher J Swiger; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

2.  Changes in weight loss and lipid profiles after a dietary purification program: a prospective case series.

Authors:  Erica Callahan
Journal:  J Chiropr Med       Date:  2013-03

3.  Changes in anthropometric measurements, body composition, blood pressure, lipid profile, and testosterone in patients participating in a low-energy dietary intervention.

Authors:  Mary Balliett; Jeanmarie R Burke
Journal:  J Chiropr Med       Date:  2013-03

4.  Statin adverse effects: patients' experiences and laboratory monitoring of muscle and liver injuries.

Authors:  Nataporn Chaipichit; Janet Krska; Thongchai Pratipanawatr; Narumol Jarernsiripornkul
Journal:  Int J Clin Pharm       Date:  2015-01-29

Review 5.  The evolution or revolution of statin therapy in primary prevention: where do we go from here?

Authors:  Patricia Rehfield; Colin Kopes-Kerr; Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2013-02       Impact factor: 5.113

Review 6.  The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?

Authors:  Michael Clearfield; Melissa Pearce; Yasmin Nibbe; David Crotty; Alesia Wagner
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

Review 7.  Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease.

Authors:  Helen H Wang; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Statins, mood, sleep, and physical function: a systematic review.

Authors:  Kristopher J Swiger; Raoul J Manalac; Michael J Blaha; Roger S Blumenthal; Seth S Martin
Journal:  Eur J Clin Pharmacol       Date:  2014-10-08       Impact factor: 2.953

9.  Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.

Authors:  Seth S Martin; Michael J Blaha; Ron Blankstein; Arthur Agatston; Juan J Rivera; Salim S Virani; Pamela Ouyang; Steven R Jones; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir
Journal:  Circulation       Date:  2013-10-20       Impact factor: 29.690

Review 10.  Clinician's guide to the updated ABCs of cardiovascular disease prevention.

Authors:  Payal Kohli; Seamus P Whelton; Steven Hsu; Clyde W Yancy; Neil J Stone; Jonathan Chrispin; Nisha A Gilotra; Brian Houston; M Dominique Ashen; Seth S Martin; Parag H Joshi; John W McEvoy; Ty J Gluckman; Erin D Michos; Michael J Blaha; Roger S Blumenthal
Journal:  J Am Heart Assoc       Date:  2014-09-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.